Who cares. What matters is NWBO designated PFS as their primary endpoint and the trial FAILED to meet the endpoint and they tossed it out. Dr. Liau designated PFS as the top efficacy measure in her Keytruda combo trial, so the argument that DCVax-L causes pseudo-PFS seems specious or she certainly wouldn't use it. Previous GBM trials have shown many treatments also can cause pseudo PFS but PFS is a commonly used metric. Again just look at Dr. Liau's protocol.
Tossing out primary endpoint that failed when a trial is virtually complete is very suspect for ANY trial. Ya think the FDA has seen every failed trial be spun into something that looks good. They will not look kindly on NWBO's protocol spin.
Market Data 
Markets 
AI
